Johnson & Johnson

JNJ is firing on both cylinders. Innovative Medicine grew 5.3% operationally with blockbuster oncology and immunology franchises offsetting STELARA biosimilar erosion. MedTech grew 5.6% operationally driven by electrophysiology and cardiovascular. They raised full-year sales guidance from $93.4B to $93.7B midpoint.